The Norovirus Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Norovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Norovirus Infections. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Norovirus Infections - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Norovirus Infections and features dormant and discontinued products.

GlobalData tracks 28 drugs in development for Norovirus Infections by 24 companies/universities/institutes. The top development phase for Norovirus Infections is preclinical with 13 drugs in that stage. The Norovirus Infections pipeline has 22 drugs in development by companies and six by universities/ institutes. Some of the companies in the Norovirus Infections pipeline products market are: Vaxart, German Cancer Research Center and Moderna.

The key targets in the Norovirus Infections pipeline products market include 3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.), Interferon Lambda Receptor 1 (Cytokine Receptor Class II Member 12 or Interleukin 28 Receptor Subunit Alpha or IL28RA or IFNLR1), and Plasmodium falciparum Circumsporozoite Protein (CSP).

The key mechanisms of action in the Norovirus Infections pipeline product include RNA Directed RNA Polymerase (EC Inhibitor with one drug in Discovery. The Norovirus Infections pipeline products include three routes of administration with the top ROA being Intramuscular and nine key molecule types in the Norovirus Infections pipeline products market including Subunit Vaccine, and Recombinant Vector Vaccine.

Norovirus Infections overview

Noroviruses are nonenveloped, positive-sense, single-stranded RNA viruses belonging to the Caliciviridae viral family. It is a highly contagious virus causing gastroenteritis, leading to stomach and intestinal inflammation. A common cause of outbreaks of diarrhea and vomiting in schools, cruise ships, hospitals, and community gatherings, it’s nicknamed the “winter vomiting bug” due to prevalence in colder months. Symptoms encompass nausea, vomiting, diarrhea, and stomach cramps, often with fever, headache, and body aches. Spread through fecal-oral transmission, it is highly contagious, with a brief incubation of 12 to 48 hours. Prevention involves rigorous hygiene, handwashing, and surface disinfection. Outbreaks require strict measures, isolating cases, and thorough cleaning. Treatment focuses on symptom management, as there’s no specific antiviral medication or vaccine available.

For a complete picture of Norovirus Infections’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.